ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Brentuximab Vedotin

Also written as “brentuximab vedotin”, “Brentuximab vedotin” and “SGN-35”.

Its studies are mostly in Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic · Lymphoma, Large B-Cell, Diffuse · Lymphoma, T-Cell, Peripheral · Melanoma, led by 3 companies.

Drug pageBrentuximab Vedotin: every studyAll 154 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 6, 201037 company-led studies, 4 open or runningNext primary completion: Mar 31, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only241 open or runningphase 3since Apr 6, 2010Feb 1, 2007none ahead
Takedaits history only113 open or runningphase 4since Jul 1, 2013Dec 12, 2011Mar 31, 2028phase 4 · NCT06831370
Bristol-Myers Squibb20 open or runningphase 3since May 1, 2017Oct 13, 2015none ahead

Also a collaborator on its studies: Merck, Takeda Development Center Americas and Ono Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2015First study: phase 2 study in Non-Hodgkin's DiseaseFirst studyNCT02581631 · 145 enrolled · United States, Canada, France and more
  2. May 1, 2017Phase 3 study in Hodgkin DiseaseNCT03138499 · 23 enrolled · United States, Japan, Puerto Rico

TargetBeta

TNF →TNFRSF8 →read by rule
“An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 8 binding agent”ChEMBL 37, by rule

Studies

All 2 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03138499Hodgkin Disease · United States, Japan, Puerto Rico3TerminatedFeb 22, 202123
NCT02581631Non-Hodgkin's Disease · United States, Canada, France and more2CompletedJan 16, 2020145

How it is read

Names in the registry

  • “brentuximab vedotin”, 27 entries
  • “Brentuximab vedotin”, 7 entries
  • “Brentuximab Vedotin”, 7 entries
  • “SGN-35”, 2 entries
  • “Brentuximab vedotin and rifampicin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.